ClinicalTrials.gg
CompletedNCT07338214Updated Apr 8, 2026

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

A Phase 1 interventional study of Petrelintide in Obesity & Overweight, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 336 studies in Obesity with a site in Germany — 73 open to participants now, 108 under way, 47 of them phase 3. Obesity · Germany.

Enrollment
225th of 274
48 · median 156
Started
2025
with 33 others
Phase 1
43 of 336
9 open now
Registered
287th of 336
by date

Among the 336 studies in Obesity with a site in Germany, this one is the 225th largest by enrollment of the 274 interventional ones that give a count, is one of 34 that started in 2025, is one of 43 in phase 1, and was the 287th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

73 of the 336 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Obesity with a site in Germany, or all of them as a file.
02

Study summary

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases.

The goal is to learn how the same single dose of petrelintide, given using different concentrations, works in the body when given to participants with a BMI at, or above, 27kg/m2.

The main questions it aims to answer are:

  1. Are there differences in how the body absorbs, distributes, metabolises and excretes petrelintide when same single dose petrelintide is given using different concentrations?
  2. Are there differences in safety of petrelintide when same single dose petrelintide is given using different concentrations?

Participants will:

Visit the study center 10 times for tests and blood sampling (9 day ambulatory visits and 1 in-house visit of 4 consecutive days with sleeping 3 nights at the study center).

Petrelintide will be given once as a single injection in a skin fold of the abdomen on Day 1. The participants will be monitored until approximately Day 50.

Read the detailed description

This is an open-label, single-center, randomized, parallel-group study designed to investigate the pharmacokinetic (PK) profiles, safety, and tolerability of a single dose administration of petrelintide administered subcutanously (SC) using 4 different drug product concentrations. The study will be conducted in participants who have a body mass index (BMI) ≥27.0 kg/m2, who will be stratified to 2 cohorts by BMI at randomization (≤38 vs >38, with 40% cap in each group).

Approximately 48 participants are needed for the study.

03

Conditions studied

  • Obesity & Overweight

Keywords

  • Pharmacokinetic
  • Obesity
  • Overweight
  • ZP8396
  • Phase 1
  • Safety and tolerability
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained before any study-related activities. Study-related activities are any procedures that would not have been done during normal management of the participant
  • : ≥27.0 kg/m2, at screening and Day -1
  • Have sufficient venous access to allow cannulation for blood sampling as required by the protocol.
  • Able and willing to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • ≥48 mmol/mol (6.5%)
  • Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg at screening
  • History of type 1 or type 2 diabetes mellitus
  • Treatment with glucose-lowering agent(s) within 90 days prior to screening
  • Obesity induced by an endocrinologic disorder (eg, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity
  • Uncontrolled thyroid disease as judged by the Investigator
  • Receipt of any medicinal product under clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomization in this study
  • Previous exposure to petrelintide (ZP8396) or exposure to other amylin analogs within the last 3 months
  • Evidence of significant neuropsychiatric disease
  • Any history or presence of a disorder or a disease, which, in the Investigator's opinion, might jeopardize the participant's safety, evaluation of results, or compliance with the protocol.
  • Known or suspected to study product or related products.
  • Known cardiovascular disease (excluding hypertension), including arthrosclerosis, , stroke, angina pectoris, or a history of myocardial infarction or coronary arterial bypass graft/percutaneous coronary intervention
  • Presence or history of clinically significant arrhythmias or clinically significant conduction disorders
  • A marked baseline prolongation of /QTc interval (eg, repeated demonstration of a QTc interval >450 ms) at screening or Day -1
  • A history of additional risk factors for Torsades de pointes (eg, heart failure, hypokalemia, family history of Long QT syndrome)
  • The use of concomitant medications that prolong the QT/QTc interval
  • Presence or history of acute or chronic pancreatitis.
  • Known clinically significant gastric emptying abnormality (for example severe gastroparesis, gastric outlet obstruction, gastric bypass operations or sleeve gastrectomy) or chronic treatment that affects gastrointestinal motility
  • History or presence of malignant neoplasms (except basal or squamous cell skin cancer or cervical carcinoma in situ) within 5 years before the screening as judged by the Investigator
  • Planned surgery scheduled during the study period, except for minor surgical procedures, as judged by the Investigator
  • Anticipated change in lifestyle (eg, eating, exercise, or sleep pattern) during the study
  • Smoking more than 5 cigarettes or the equivalent nicotine consumption per day (including use of nicotine preparations)
  • Inability or unwillingness to refrain from smoking and use of nicotine substitute products 1 day before and during the inpatient period
  • Any use of chronic (>14 days) systemic therapy (excluding topical, intraocular, intranasal, single intraarticular injection, or inhaled preparations) within 90 days of screening
  • Any medication (prescription and non-prescription drugs) except for stable treatment with antihypertensive and lipid-lowering drugs as well as thyroid replacement therapy, unless approved by the medical monitor in consultation with the Sponsor (Note: Stable treatment with antihypertensive and lipid lowering drugs (stable for ≥1 month prior to screening) as well as thyroid replacement therapy (≥2 months prior to screening) will be allowed. Use of routine vitamins, topical treatments (including local acting steroids/antihistamines for the treatment of mild hay fever), menopausal hormone replacement therapy, and are allowed. In addition, occasional use of acetylsalicylic acid, paracetamol, and ibuprofen for acute pain treatment is allowed.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Arm A

    Each participant will receive a single subcutaneous dose of petrelintide strength A on Day 1.

    Drug: Petrelintide

  • Active comparator
    Arm B

    Each participant will receive a single subcutaneous dose of petrelintide strength B on Day 1.

    Drug: Petrelintide

  • Active comparator
    Arm C

    Each participant will receive a single subcutaneous dose of petrelintide strength C on Day 1.

    Drug: Petrelintide

  • Active comparator
    Arm D

    Each participant will receive a single subcutaneous dose of petrelintide strength D on Day 1.

    Drug: Petrelintide

Interventions

  • Solution administered with a syringe

    Also known as: ZP8396

06

What researchers measure

Primary outcomes

  1. To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Area under the petrelintide plasma concentration time curve from time zero to infinity after a single dose of petrelintide (AUC0-inf)

    Time frame: Day 1 - day 50 (+/- 2)

  2. To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Maximum observed plasma concentration (Cmax) from time zero to infinity after a single dose of petrelintide

    Time frame: Day 1 - day 50 (+/- 2)

Secondary outcomes

  1. To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Area under the petrelintide plasma concentration time curve from time zero to last measurable concentration after a single dose of petrelintide (AUC0-t)

    Time frame: Day 1 - day 50 (+/- 2)

  2. To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Time to maximum observed petrelintide plasma concentration after a single dose of petrelintide (Tmax)

    Time frame: Day 1 - day 50 (+/- 2)

  3. To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Terminal elimination half-life for petrelintide after a single dose of petrelintide (t1/2)

    Time frame: Day 1 - day 50 (+/- 2)

  4. To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Apparent clearance of petrelintide after a single dose of petrelintide (CL/F)

    Time frame: Day 1 - day 50 (+/- 2)

  5. To investigate the safety and tolerability of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity

    Incidence of treatment-emergent adverse events (TEAEs) from dosing (Day 1) to end of follow-up

    Time frame: Day 1 - day 50 (+/- 2)

07

Study locations

1 site
  • Charité Research Organisation GmbH
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Mar 2026, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 13, 2026
StartActual
Dec 17, 2025
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338214
Lead sponsor
Zealand Pharma
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Dec 17, 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Apr 8, 2026

Study contacts

Martha Haidacher
principal investigator · Charité Research Organisation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petrelintide

Start the discussion